← All trials
NCT02221063
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2014
- Primary completion
- Apr 30, 2015
- Completion date
- Apr 30, 2016
- First posted
- Aug 20, 2014
- Last posted
- May 25, 2016
- Enrollment
- 366
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of British ColumbiaLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- Grand Challenges CanadaCollaborator
- Helen Keller InternationalCollaborator
- Helen Keller InternationalStudy chair
- International Development Research Centre, CanadaCollaborator
- University of British ColumbiaOverall official - principal investigator
- University of British ColumbiaStudy chair
- University of British ColumbiaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.